Immunotherapy 'could benefit prostate cancer patients'

Men given just months or weeks to live after being diagnosed with prostate cancer are surviving for more than a year thanks to a breakthrough in immunotherapy treatment, a trial has shown.Almost 40% of patients who spent 12 months on the drug pembrolizumab - known as a "checkpoint inhibitor" - as part of a new study were still alive and one in 10 had not seen the cancer grow.The 258 men with advanced prostate cancer were treated with the drug as part of a trial led by a team at the Institute of